Technical Analysis for REPL - Replimune Group, Inc.

Grade Last Price % Change Price Change
grade A 14.98 2.04% 0.30
REPL closed up 2.04 percent on Monday, December 17, 2018, on 3.1 times normal volume.
0 Watchers
View Intraday Alerts Watchlist Portfolio

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Up Up
See historical REPL trend table...

Date Alert Name Type % Chg
Dec 17 20 DMA Support Bullish 0.00%
Dec 17 MACD Bullish Signal Line Cross Bullish 0.00%
Dec 17 Pocket Pivot Bullish Swing Setup 0.00%
Dec 17 Volume Surge Other 0.00%
Dec 17 Outside Day Range Expansion 0.00%
Dec 17 Upper Bollinger Band Touch Strength 0.00%
Dec 14 20 DMA Support Bullish 2.04%
Dec 13 20 DMA Support Bullish 0.27%
Dec 13 Pocket Pivot Bullish Swing Setup 0.27%
Dec 12 Crossed Above 20 DMA Bullish 2.78%

Older signals for REPL ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Get Started for Free!
Configure default chart indicators
Basic chart:

Profile
  • Earnings date: 2018-11-29
Replimune Group, Inc. is a clinical-stage biotechnology company. The Company is engaged in the field of oncolytic immunotherapy to treat the cancer patients. The Company applies its Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The Company is focused on developing a pipeline of oncolytic immunotherapy product candidates to provide clinical benefits to cancer patients. Its product candidates include RP, RP2, and RP3. The Company is focused on Phase 1/2 clinical trial with its lead product candidate, RP1, in approximately 150 patients with a range of solid tumors.
Is REPL a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 0 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Recent News
Date Title
Dec 12 Replimune (REPL) Presents At BMO 2018 Prescriptions for Success Healthcare Conference - Slideshow
Dec 8 RA Capital Was Wrong about Achillion Pharmaceuticals, Inc. (ACHN): Is it Time To Buy?
Dec 5 Replimune to Present at the BMO Capital Markets 2018 Prescriptions for Success Healthcare Conference
Nov 14 Bain Capital Life Sciences Investors, LLC Buys Replimune Group Inc
Nov 14 Replimune Group reports Q2 results
Nov 14 Replimune Reports Financial Results for the Second Fiscal Quarter, Ended September 30, and Provides Development and Corporate Update
Oct 12 Midday Gainers / Losers
Oct 10 The Daily Biotech Pulse: Novartis Blood Disorder Drug Improves Patient Outcomes, Audentes To Offer Shares
Oct 9 The Daily Biotech Pulse: Affimed's Cancer Drug Placed On Clinical Hold, Celgene's Positive Scalp Psoriasis Trial
Sep 26 Replimune to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology
See more REPL news...
Indicators
Indicator Value
52 Week High 23.55
52 Week Low 10.52
Average Volume 34,495
200-Day Moving Average 0.0
50-Day Moving Average 13.6025
20-Day Moving Average 14.5588
10-Day Moving Average 14.5805
Average True Range 1.2143
ADX 19.26
+DI 15.0141
-DI 12.0828
Chandelier Exit (Long, 3 ATRs ) 11.8571
Chandelier Exit (Short, 3 ATRs ) 15.9329
Upper Bollinger Band 15.4174
Lower Bollinger Band 13.7002
Percent B (%b) 0.75
BandWidth 11.794928
MACD Line 0.1631
MACD Signal Line 0.1542
MACD Histogram 0.0089
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 17.22
Resistance 3 (R3) 17.14 16.32 16.84
Resistance 2 (R2) 16.32 15.75 16.36 16.72
Resistance 1 (R1) 15.65 15.40 15.99 15.73 16.59
Pivot Point 14.83 14.83 15.00 14.87 14.83
Support 1 (S1) 14.16 14.26 14.50 14.24 13.37
Support 2 (S2) 13.34 13.91 13.38 13.24
Support 3 (S3) 12.67 13.34 13.12
Support 4 (S4) 12.75